Close to half of injecting drug users surveyed in South Africa are living with the potentially deadly Hepatitis C virus, a new study has found. But a drug that could cure them, and that is used in several countries, remains unavailable in South Africa.
- Published
- 15 August 2018
- From
-
Bhekisisa
The number of Australians dying from liver failure and liver cancer related to hepatitis C has dropped by 20 per cent in just two years, according to preliminary data released today by The Kirby Institute.
- Published
- 13 August 2018
- From
-
ABC News
Providing cheap drugs against the hepatitis C virus (HCV) has had limited success in fighting the disease in South-East Asia where poor health services and stigma surrounding the infection are significant barriers, says a new survey.
- Published
- 30 July 2018
- From
-
SciDev.Net
Most supervised drug
consumption facilities offer hepatitis C virus (HCV) testing and referrals, but
very few offer treatment, indicating that they could potentially play a greater
role in
- Published
- 27 July 2018
- By
- Liz Highleyman
People living with HIV and hepatitis C (HCV) who have a history of injecting drug use are being offered less effective, but cheaper, HCV medication than other people with HIV/HCV co-infections, new research from France finds.
- Published
- 17 July 2018
- From
-
AVERT
Transplanting hepatitis C-infected dialysis patients with HCV-positive donor organs and then treating the infection later is more effective, cheaper and shortens organ wait time.
- Published
- 10 July 2018
- From
-
Eurekalert Inf Dis
State prisons across the U.S. are failing to treat at least 144,000 inmates who have hepatitis C, a curable but potentially fatal liver disease, according to a recent survey and subsequent interviews of state corrections departments.
- Published
- 09 July 2018
- From
-
Kaiser Health News
Curing hepatitis C is a priority for people also living with HIV.
- Published
- 27 June 2018
- From
-
POZ
The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a legal patent challenge today at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent it granted to US pharmaceutical corporation Gilead Sciences in 2012 for the oral hepatitis C medicine velpatasvir. This unmerited patent means this lifesaving medicine could remain priced out of reach for several more years, leaving millions of people to unnecessarily go without in China and abroad.
- Published
- 20 June 2018
- From
-
MSF press release
Since the last global update in 2017, Italy, Spain, Switzerland, the UK and Mongolia have all been added to the list, thanks to the number of patients they treated in 2017, plus the lifting of treatment restrictions to include all patients with hepatitis C regardless of their degree of liver damage. These countries join the others already on track to eliminate by 2030: Australia, Egypt, France, Georgia, Iceland, Japan and the Netherlands. In all cases, these countries are treating at least 7% of their infected population each year, and have opened treatment up to all those infected.
- Published
- 18 June 2018
- From
-
CDA Foundation
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...